Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib in First-Line GIST
NCT00785785Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial of nilotinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Novartis. Primary endpoint: Progression-Free Survival at 37 months. Started Mar 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00785785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785785.